Gartner, Inc. Amortization of Deferred Sales Commissions
Gartner, Inc. (IT) reported Amortization of Deferred Sales Commissions of $612.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfDeferredSalesCommissions · last filed 2026-02-12
- Gartner, Inc. amortization of deferred sales commissions for the quarter ending 2018-12-31 was $80.90M, a 21.29% increase year-over-year.
- Gartner, Inc. amortization of deferred sales commissions for the quarter ending 2018-09-30 was $71.20M, a 20.88% increase year-over-year.
- Gartner, Inc. amortization of deferred sales commissions for the quarter ending 2018-06-30 was $76.80M, a 40.40% increase year-over-year.
- Gartner, Inc. amortization of deferred sales commissions for the quarter ending 2018-03-31 was $75.90M, a 51.20% increase year-over-year.
- Gartner, Inc. amortization of deferred sales commissions for fiscal 2025 was $612.30M, a 6.62% increase from fiscal 2024.
- Gartner, Inc. amortization of deferred sales commissions for fiscal 2024 was $574.30M, a 4.32% increase from fiscal 2023.
- Gartner, Inc. amortization of deferred sales commissions for fiscal 2023 was $550.50M, a 2.06% decline from fiscal 2022.
- Gartner, Inc. amortization of deferred sales commissions for fiscal 2022 was $562.10M, a 18.96% increase from fiscal 2021.
| Period end | Amortization of Deferred Sales Commissions 3 month | Amortization of Deferred Sales Commissions 6 month | Amortization of Deferred Sales Commissions 9 month | Amortization of Deferred Sales Commissions 12 month |
|---|---|---|---|---|
| 2025-12-31 | $612.30M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $574.30M 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $550.50M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $562.10M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $472.50M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $440.50M 10-K · filed 2023-02-16 | |||
| 2019-12-31 | $369.50M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $80.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $152.10M derived: sum of 2 quarters · filed 2021-02-24 | $228.90M derived: sum of 3 quarters · filed 2021-02-24 | $304.80M 10-K · filed 2021-02-24 |
| 2018-09-30 | $71.20M 10-Q · filed 2018-11-01 | $148.00M derived: sum of 2 quarters · filed 2018-11-01 | $223.90M 10-Q · filed 2018-11-01 | $290.60M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $76.80M 10-Q · filed 2018-08-01 | $152.70M 10-Q · filed 2018-08-01 | $219.40M derived: sum of 3 quarters · filed 2020-02-19 | $278.30M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $75.90M 10-Q · filed 2018-05-08 | $142.60M derived: sum of 2 quarters · filed 2020-02-19 | $201.50M derived: sum of 3 quarters · filed 2020-02-19 | $256.20M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $66.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $125.60M derived: sum of 2 quarters · filed 2020-02-19 | $180.30M derived: sum of 3 quarters · filed 2020-02-19 | $230.50M 10-K · filed 2020-02-19 |
| 2017-09-30 | $58.90M 10-Q · filed 2018-11-01 | $113.60M derived: sum of 2 quarters · filed 2018-11-01 | $163.80M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $54.70M 10-Q · filed 2018-08-01 | $104.90M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $50.20M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $180.20M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evolent Health, Inc. (EVH) | United States | $0.397B | -1.21 |
| FRANKLIN COVEY CO (FC) | United States | $0.195B | 123.76 |